- Home
- CANF vs ZIMV Comparison
CANF vs ZIMV Comparison
Compare CANF & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ZIMV
- Stock Information
- Founded
- CANF 1994
- ZIMV 2021
- Country
- CANF Israel
- ZIMV United States
- Employees
- CANF N/A
- ZIMV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CANF Health Care
- ZIMV Health Care
- Exchange
- CANF Nasdaq
- ZIMV Nasdaq
- Market Cap
- CANF 7.9M
- ZIMV 262.9M
- IPO Year
- CANF N/A
- ZIMV N/A
- Fundamental
- Price
- CANF $1.13
- ZIMV $9.44
- Analyst Decision
- CANF Strong Buy
- ZIMV Hold
- Analyst Count
- CANF 2
- ZIMV 1
- Target Price
- CANF $14.00
- ZIMV N/A
- AVG Volume (30 Days)
- CANF 423.1K
- ZIMV 141.2K
- Earning Date
- CANF 05-06-2025
- ZIMV 05-08-2025
- Dividend Yield
- CANF N/A
- ZIMV N/A
- EPS Growth
- CANF N/A
- ZIMV N/A
- EPS
- CANF N/A
- ZIMV N/A
- Revenue
- CANF $674,000.00
- ZIMV $449,749,000.00
- Revenue This Year
- CANF $461.72
- ZIMV $2.13
- Revenue Next Year
- CANF N/A
- ZIMV $2.44
- P/E Ratio
- CANF N/A
- ZIMV N/A
- Revenue Growth
- CANF N/A
- ZIMV N/A
- 52 Week Low
- CANF $1.22
- ZIMV $8.56
- 52 Week High
- CANF $4.69
- ZIMV $22.40
- Technical
- Relative Strength Index (RSI)
- CANF 35.40
- ZIMV 38.58
- Support Level
- CANF $1.14
- ZIMV $9.25
- Resistance Level
- CANF $1.27
- ZIMV $9.74
- Average True Range (ATR)
- CANF 0.12
- ZIMV 0.58
- MACD
- CANF -0.02
- ZIMV 0.12
- Stochastic Oscillator
- CANF 0.00
- ZIMV 53.66
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.